The leading trade body for the UK pharmaceutical industry has appointed a new president, current Pfizer UK managing director Susan Rienow.
The Association of the British Pharmaceutical Industry (ABPI) has faced a degree of criticism in recent months over a marketing code breach from one of its members, Novo Nordisk (NOV: N).
The Danish company was suspended from the ABPI after a “disguised” promotional campaign for weight loss treatment Saxenda (liraglutide) was uncovered. The affair led to the resignation of ABPI president Pinder Sahota, who is also UK country manager for Novo Nordisk, a diabetes care specialist.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze